Trial · NCT07071844
BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients
NCT07071844, Phase 2, Not yet recruiting, GERCOR - Multidisciplinary Oncology Cooperative Group
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients. Trials, record NCT07071844. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07071844
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients
- NCT number
- NCT07071844
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 162 participants, estimated
- Lead sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Trifluridine/tipiracil, Bevacizumab
- First posted
- 2025-07-17
- Last updated
- 2025-07-17
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The occurrence of at least one grade 3-4 neutropenia | From randomization up to 14 days after the end of treatment | The occurrence of 3-4 neutropenia in mCRC patients undergoing treatment with the combination of bevacizumab and bi-weekly administration of trifluridine/tipiracil (experimental arm) compared to a conventional administration (control arm). |
| Secondary | Overall survival (OS) | From the date of randomization to the date of death from any cause, assessed up to 3 years | OS in both arms; calculated from the date of randomization to the date of death from any cause. |
| Secondary | Progression-free survival (PFS) | From randomization to the date of the first documented disease progression or death due to any cause, up to 3 years | PFS in both arms; defined as the time from randomization to the date of the first documented PD determined by the Investigator assessment by RECIST 1.1 or death due to any cause, whichever occurs first |
| Secondary | Best overall response (BOR) | From randomization to the date of progression, death or subsequent anti-cancer therapy, up to 3 years | BOR according to Response Evaluation Criteria Solid Tumors (RECIST) v1.1 in both arms; defined as the best response designation (CR, PR, SD or PD), evaluated on all radiological evaluations available and related to study treatment period. |
| Secondary | Disease control rate (DCR) | Up to achievement of best overall response (BOR) of CR or PR or SD, up to 3 years | DCR in both arms according to RECIST v1.1; defined as at least a CR, PR or SD radiological evaluation designation on all radiological evaluations available and related to study treatment period. |
| Secondary | Incidence and grade of adverse events (AEs) and serious adverse events (SAEs) [Safety and tolerability] | Assessed 28 days after the last administration of treatment or after the end of the treatment visit | Incidence and grade of AEs and SAEs, according to NCI-CTCAE v 5.0 in both arms |
| Secondary | Eastern Cooperative Oncology Group performance status (ECOG PS) deterioration | Time from baseline up to 3 years | ECOG PS deterioration is defined as the first increase of at least one point from baseline. The ECOG PS scale ranges from 0 (fully active, asymptomatic) to 4 (completely bedridden), with higher scores indicating worse functional status and poorer prognosis. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07071844
GET https://conductscience.org/api/trials/v1/NCT07071844/registered